Long-term treatment experience in a subject with Dunnigan-type familial partial lipodystrophy: Efficacy of rosiglitazone

Diabetic Medicine

Volumn 22, Issue 11, 2005, Pages 1611-1613

  Ludtke A ^a   Heck, K ^b   Genschel, J ^a   Mehnert, H ^c   Spuler, S ^a   Worman, H J ^d   Schmidt, Hartmut ^a,e  

^a HUMBOLDT UNIVERSITY   (Germany)

^b Academic Hospital Munich Schwabing ^*

^c Klinikum Schwabing   (Germany)

^d University Hospital of Münster ^*  (Germany)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Diabetes; Familial partial lipodystrophy; Hyperlipidaemia; Insulin resistance; Thiazolidinedione

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; LAMIN A; LAMIN C; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; DYSLIPIDEMIA; FAMILIAL DISEASE; FAMILIAL PARTIAL LIPODYSTROPHY; FEMALE; GENE; GENE MUTATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPODYSTROPHY; LMNA GENE; OBESITY; PATHOPHYSIOLOGY;

EID: 27844530578     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01757.x     Document Type: Article

References (9)

1. Dunnigan MG, Cochrane MA, Kelly A, Scott JW. Familial lipoatrophic diabetes with dominant transmission. A new syndrome. Quart J Med 1974; 43: 33-48.
2. Köbberling J, Willms B, Kattermann R, Creutzfeldt W. Lipodystrophy of the extremities. A dominantly inherited syndrome associated with lipatrophic diabetes. Humangenetik 1975; 29: 111-120.
3. Schmidt HH, Genschel J, Baier P, Schmidt M, Ockenga J, Tietge UJ et al. Dyslipemia in familial partial lipodystrophy caused by an R482W mutation in the LMNA gene. J Clin Endocrinol Metab 2001; 86: 2289-2295.
4. Vigouroux C, Magre J, Vantyghem MC, Bourut C, Lascols O, Shackleton S et al. Lamin A/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy. Diabetes 2000; 49: 1958-1962.
5. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000; 133: 263-274.
6. Parker JC. Troglitazone: the discovery and development of a novel therapy for the treatment of type 2 diabetes mellitus. Adv Drug Deliv Rev 2002; 54: 1173-1197.
7. Owen KR, Donohoe M, Ellard S, Hattersley AT. Response to treatment with rosiglitazone in familial partial lipodystrophy due to a mutation in the LMNA gene. Diabet Med 2003; 20: 823-827.
8. Vantyghem MC, Pigny P, Maurage CA, Rouaix-Emery N, Stojkovic T, Cuisset JM et al. Patients with familial partial lipodystrophy of the Dunnigan type due to a LMNA R482W mutation show muscular and cardiac abnormalities. J Clin Endocrinol Metab 2004; 89: 5337-5346.
9. Normen L, Frohlich J, Montaner J, Harris M, Elliot T, Bondy G. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol. Diabetes Care 2004; 27: 2241-2242.